| Abstrakt: |
A recent report from Ningxia Medical University discusses the research on the therapeutic efficacy of metformin in improving diabetic bladder dysfunction (DBD) by targeting the TXNIP-NLRP3-GSDMD pathway. The study involved treating mice with metformin, which resulted in improved glucose tolerance, insulin sensitivity, and bladder function. Metformin was found to ameliorate urothelial cell damage in DBD mice by inhibiting TXNIP generation and reducing NLRP3 and GSDMD production. The research was supported by various funding sources and can be accessed for further information in Scientific Reports. [Extracted from the article] |
